Evidence map›Paper›PMID 40766526›Full record

ArticlebioRxiv : the preprint server for biology2025

Bacterial type II topoisomerases cleave DNA in a species-specific manner.

Ian L Morgan, Jeffrey Y Jian, Neil Osheroff, Keir C Neuman

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Ian L MorganNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6772-6883
Jeffrey Y JianDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-5169-1396
Neil OsheroffDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-2550-4884
Keir C NeumanNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0863-5671

Funding

Single-molecule measurements of DNA topology and topoisomerasesZIAHL001056 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI NEUMAN, KEIR · 2009 to 2025
$22.6M
Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted AntibacterialsR01AI170546 · NIAID · VANDERBILT UNIVERSITY · PI NEIL OSHEROFF · 2023 to 2026
$2.7M
Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted AgentsR01GM126363 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 2018 to 2025
$2.6M
Testing Direct Effects of Topological and Mechanical Stress on Enhancing Anticancer and Antibacterial Drugs that Target Type II TopoisomerasesFI2GM142536 · NIGMS · U.S. NATIONAL HEART LUNG AND BLOOD INST · PI MORGAN, IAN LEWIS · 2022 to 2022
–
Intramural NIH HHS ZIA HL001056NIAID NIH HHS R01 AI170546NIGMS NIH HHS FI2 GM142536NIGMS NIH HHS R01 GM126363
6 · The paper itself

Abstract

The type II topoisomerases, gyrase and topoisomerase IV, are essential enzymes in nearly all bacteria and are the targets of fluoroquinolones, which are some of the most widely prescribed broad-spectrum antibacterials in clinical use. As part of their catalytic cycle, gyrase and topoisomerase IV transiently cleave DNA in a sequence-dependent manner. However, it is unclear whether this sequence-dependence is species-specific. Therefore, using our recently developed SHAN-seq method, we mapped and compared cleavage sites for type II topoisomerases from three different pathogenic bacterial species,

Identifiers

PMID40766526
PMCPMC12324340

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.